Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
November 25, 2016 6:48 AM ESTSunTrust Robinson Humphrey downgraded Juno Therapeutics (NASDAQ: JUNO) from Buy to Hold with a price target of $25.00 (from $48.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL was placed on clinical hold for the second time.
The analyst sees reduced visibility and increased... More
Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group
November 23, 2016 1:51 PM ESTMaxim Group analyst Jason McCarthy lowered his price target on Juno Therapeutics (NASDAQ: JUNO) to $34.00 (from $50.00) after the ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. The firm maintained a Buy rating.
McCarthy highlighted:
The ROCKET study evaluating JCAR015 in no-option Adult ALL (Acute Lymphoblastic Leukemia) was placed on clinical hold for the second time. Two more patients died due to treatment-related neurotoxicity (cerebral edema), the same cause of death observed in July when ROCKET was... MoreJuno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call
November 23, 2016 8:44 AM ESTJuno Therapeutics (NASDAQ: JUNO) CEO Hans Bishop said that the second JCAR015 patient with brain swelling has died, according to the company's conference call on Wednesday. Patients who died were treated last week, the CEO noted.
The company has treated 12 patients since... More
Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold
November 23, 2016 8:33 AM ESTJuno Therapeutics (NASDAQ: JUNO) resumed trading down 40% after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the ROCKET trial. The clinical... More
Juno Therapeutics (JUNO) to Resume Trading at 8:30AM ET after Clinical Hold Announced
November 23, 2016 8:05 AM ESTJuno Therapeutics (NASDAQ: JUNO) set to resume trading at 8:30AM ET after it voluntarily placed on hold the Phase II clinical trial of JCAR015
... MoreJuno Therapeutics (JUNO) Halted for News Release
November 23, 2016 8:01 AM ESTJuno Therapeutics (NASDAQ: JUNO) Halted for News Release
... More